Reversal of Moderate or Superficial Neuromuscular Blockade Induced by Cisatracurium
Status:
Recruiting
Trial end date:
2021-12-15
Target enrollment:
Participant gender:
Summary
The administration of acetylcholinesterase inhibiting agents (such as neostigmine) has been
used to reverse the muscle paralysis induced by non-depolarizing neuromuscular blocking
agents. It is not well known whether there is a difference between the time required for
complete reversion of moderate neuromuscular blockade (NMB) after the administration of
neostigmine in usual doses when compared to the reversion of superficial NMB with the use of
a reduced dose of the same agent (excessive doses of neostigmine administered during
superficial blocks may cause paradoxical muscle weakness). The aim of the present study will
be to compare, by means of a prospective, randomized, controlled and double-blind clinical
trial, the times necessary for the reversion of moderate block with neostigmine 60 mcg / kg
or for superficial block to reach values of T4 / T1> 0.9 using neostigmine 30 mcg / kg.